PXI Auto Components
301560
Shenzhen Crastal Technology
300824
Shenzhen Zesum Technology
301486
4
Hanjia Design Group
300746
5
Harbin Jiuzhou Group
300040
CN Stock MarketDetailed Quotes
603669 Lionco Pharmaceutical Group
- 4.38
- -0.24-5.19%
Market Closed Apr 25 15:00 CST
3.16BMarket Cap-24.20P/E (TTM)
4.55High4.34Low454.66KlotVolume4.53Open4.62Pre Close201.01MTurnover6.30%Turnover RatioLossP/E (Static)721.24MShares9.5452wk High4.46P/B3.16BFloat Cap3.4552wk Low5.08Limit Up721.24MShs Float20.05Historical High4.16Limit Down4.55%Amplitude2.94Historical Low--Dividend TTM4.42Avg Price210.55KlotAsk--Div YieldTTM100Lot Size215.36KlotBid
Lionco Pharmaceutical Group News
Insider Information Insider Registration Management System (Revised in April 2025)
Fund Raising Management System (Revised in April 2025)
CITIC Securities Co., Ltd.\'s inspection opinions on the storage and use of funds raised by Lingkang Pharmaceutical Group Co., Ltd. in 2024
Special inspection report on the 2024 operating income deduction table of Lingkang Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the 27th Meeting of the Fourth Board of Directors
Verification report on the storage and actual use of funds raised by Lingkang Pharmaceutical Group Co., Ltd.
Special report on the annual storage and use of raised funds
Special Opinions of the Board of Directors of Lingkang Pharmaceutical Group Co., Ltd. on the 2024 Independence Assessment of Independent Directors
Independent Director\'s 2024 Annual Debriefing Report - Pan Ziqiang
Independent Director\'s 2024 Annual Debriefing Report-Before
Internal Control Audit Report of Lingkang Pharmaceutical Group Co., Ltd.
Independent Director\'s 2024 Annual Debriefing Report - He Chao
Special audit report on the summary table of non-operating capital occupation and other related capital transactions of Lingkang Pharmaceutical Group Co., Ltd.
2024 Annual Audit Report
Announcement of Resolutions of the 17th Meeting of the Fourth Board of Supervisors
Announcement on the retirement and resignation of the company\'s deputy general manager
Lingkang Pharmaceutical: Legal Opinion of Shanghai Oriental Huayin Law Firm on the resale of convertible corporate bonds of Lingkang Pharmaceutical Group Co., Ltd.
Lingkang Pharmaceutical: Announcement on the Wholly-owned Subsidiary Obtaining a Registration Certificate for Naloxone Hydrochloride Injection
Lingkang Pharmaceutical: Announcement on Abnormal Fluctuations in Stock Trading
Notice of abnormal fluctuations in stock trading